✦ LIBER ✦

Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion

✍ Scribed by Ezekowitz, Michael D.; Cappato, Riccardo; Klein, Allan L.; Camm, A. John; Ma, Chang-Sheng; Le Heuzey, Jean-Yves; Talajic, Mario; Scanavacca, Maurício I.; Vardas, Panos E.; Kirchhof, Paulus; Hohnloser, Stefan H.; Hemmrich, Melanie; Lanius, Vivian; Meng, Isabelle Ling; Wildgoose, Peter; van Eickels, Martin

Book ID: 121804285
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 196 KB
Volume: 167
Category: Article
ISSN: 1097-6744
DOI: 10.1016/j.ahj.2013.12.024

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Intracranial Hemorrhage Among Patients W

Intracranial Hemorrhage Among Patients With Atrial Fibrillation Anticoagulated With Warfarin or Rivaroxaban: The Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation

✍ Hankey, G. J.; Stevens, S. R.; Piccini, J. P.; Lokhnygina, Y.; Mahaffey, K. W.; 📂 Article 📅 2014 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 920 KB

Rivaroxaban—Once daily, oral, direct fac

Rivaroxaban—Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF study

📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 242 KB

Letter by Apostolakis et al Regarding Ar

Letter by Apostolakis et al Regarding Article, “Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R 2 CHADS 2 Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts”

✍ Apostolakis, Stavros ;Lane, Deirdre A. ;Banerjee, Amitava 📂 Article 📅 2013 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 419 KB